Yosuke Kawashima

7PUBLICATIONS
56CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Mar 31, 2025
Randomized Phase III Study of EGFR Tyrosine Kinase Inhibitor and Intercalated Platinum-Doublet Chemotherapy for Non-Small Cell Lung Cancer Harboring EGFR Mutation.

Shintaro Kanda, Seiji Niho, Takayasu Kurata

|Oct 11, 2024
Association between Immune-Related Adverse Events and Atezolizumab in Previously Treated Patients with Unresectable Advanced or Recurrent Non-Small Cell Lung Cancer.

Hidetoshi Hayashi, Makoto Nishio, Hiroaki Akamatsu

|Jul 25, 2024
Successful Application of Tocilizumab in a Patient With Neoadjuvant Immunochemotherapy-Induced Cytokine Release Syndrome.

Soichiro Minami, Yosuke Kawashima, Yasuhiko Munakata

|Jan 12, 2024
Successful application of lorlatinib in a 23-year-old patient with anaplastic lymphoma kinase (ALK)-positive lung cancer and multiple brain metastases.

Yosuke Murakami, Yosuke Kawashima, Shinji Chiba

|Sep 12, 2023
Efficacy of paclitaxel-carboplatin with bevacizumab as a late-line therapy for patients with advanced nonsquamous non-small cell lung cancer: A platinum rechallenge.

Jun Sugisaka, Yukihiro Toi, Yosuke Kawashima

|Aug 17, 2023
Phase II trial of daily S-1 combined with weekly irinotecan in previously treated patients with advanced or recurrent squamous cell lung cancer: North Japan lung cancer group 1101.

Yosuke Kawashima, Osamu Ishimoto, Eisaku Miyauchi

Pageof 2

Frequent Collaborators

2 joint publications

Toshihiro Misumi

2 joint publications

Satoru Miura

2 joint publications

Akihiro Bessho

1 joint publications

Yuri Taniguchi